# Curriculum Vitae

## Personal information

Harald Weninger

## Work experience

1. Employer: AXON_Neuroscience
   - Start date: 052001
   - End date: 112006
   - Position: Staff scientist
   - Activities: Molecular and cell biological method development for characterization of small molecules against Alzheimer's disease. Set up of in_vitro ADME_Tox Systems.
   - Country: Austria
2. Employer: AFFIRIS
   - Start date: 012007
   - End date: 042015
   - Position: Project leader
   - Activities: Preclinical peptide_vaccine development against Parkinson's disease to Phase 1 (IMPD and IB). Quality control.
   - Country: Austria
3. Employer: AGES
   - Start date: 062015
   - End date:
   - Position: Quality Assessor
   - Activities: Assessment of Quality relevant parts of the dossier for marketing authorization of small molecules and biologicals for human and veterinary medicinal products.
   - Country: Austria

## Education and training

1. Subject: Institute for Biochemistry
   - Start date: 031996
   - End date: 051997
   - Qualification: Magister rer. nat.
   - Organisation: Molecular_biological techniques, Cell_biological techniques for Protein characterization.
   - Country: Austria
2. Subject: Children`s Cancer Research Institute
   - Start date: 051997
   - End date: 122002
   - Qualification: Dr rer. nat.
   - Organisation: Molecular_biological techniques, Cell_biological techniques for the detection of Minimal Residual Disease in Chronic Myeloid Leukemia and Neuroblastoma patients.
   - Country: Austria

## Additional information

### Publications

1. Active immunization against alpha_synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mandler M, Valera E, Rockenstein E, Mante M, Weninger H, Patrick C, Adame A, Schmidhuber S, Santic R, Schneeberger A, Schmidt W, Mattner F, Masliah E. Mol Neurodegener. 2015 Mar 19;10:10. doi: 10.1186/s13024_015_0008_9. 2. Next_generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Mandler M, Valera E, Rockenstein E, Weninger H, Patrick C, Adame A, Santic R, Meindl S, Vigl B, Smrzka O, Schneeberger A, Mattner F, Masliah E. Acta Neuropathol. 2014;127(6):861_79. doi: 10.1007/s00401_014_1256_4. Epub 2014 Feb 14. 3. Ubiquitination is required for the retro_translocation of a short_lived luminal endoplasmic reticulum glycoprotein to the cytosol for degradation by the proteasome. de Virgilio M, Weninger H, Ivessa NE. J Biol Chem. 1998 Apr 17;273(16):9734_43. 4. A small nuclear RNA, hdm365, is the major processing product of the human mdm2 gene. Bartl S, Ban J, Weninger H, Jug G, Kovar H. Nucleic Acids Res. 2003 Feb 15;31(4):1136_47.

### Projects

1. MIMOTOPES OF ALPHA_SYNUCLEIN AND VACCINES THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS US2017158744 (A1) 2. USE OF MIMOTOPES OF ALPHA_SYNUCLEIN EPITOPES FOR TREATING LEWY BODY DISEASES CY1117582 (T1) 3. AD VACCINE ES2392789 (T3)

### Memberships

### Other Relevant Information